Major new awards program honors cancer researcher

January 20, 2006

The Vilcek Foundation today announced that Joan Massagué, Program Chairman, Cancer Biology and Genetics, Memorial Sloan-Kettering Cancer Center, will receive the inaugural Vilcek Prize in Biomedical Research. This major new prize is designed to honor foreign-born scientists who have made extraordinary contributions to biomedical research in the United States.

The only national award to honor outstanding creative achievement by immigrants to America, The Vilcek Prize is accompanied by a $50,000 cash award. In conjunction with the prize, the Foundation is launching an annual lecture at New York University School of Medicine. Dr. Massagué, who was born in Barcelona, Spain, will deliver the first Vilcek Foundation Prize lecture on Thursday, March 16, at 4 pm, speaking on the subject of "Controlling Cell Behavior: From Cytostasis to Metastasis."

Having chaired Memorial Sloan-Kettering's Cell Biology program for nearly 15 years, today Dr. Massagué leads its Cancer Biology and Genetics program. He is also a Howard Hughes Medical Institute Investigator and was elected in 2000 to the National Academy of Sciences.

Dr. Massagué's work in this country has shed light on the molecular mechanism of action of a crucial family of growth factors that regulate cell behavior and embryonic development. Disruption of these pathways can underlie cancers, inherited disorders and other diseases. Dr. Massagué's work has also helped to elucidate genetic changes in cancer cells that determinetheir ability to disseminate to distant parts of the body. For this research, Dr. Massagué was honored in 2004 with Spain's most prestigious prize, the Prince of Asturias Award for Scientific and Technical Research, which is given annually to leading scientists from around the world.

Dr. Massagué is not the only member of his family to contribute to American society: upon moving to the United States, his wife Roser, also born in Barcelona, pursued degrees in education and psychology and today is a superintendent in the New York City public schools system.

Dr. Jan T. Vilcek, a professor and research scientist at the New York University School of Medicine, and Marica F. Vilcek, an art historian, established The Vilcek Foundation in 2000 as a way to honor achievement in their respective fields and to show appreciation for the opportunities they received as newcomers to the United States. The Vilceks came to the United States in the 1960s as refugees from former communist Czechoslovakia.

"In launching the Vilcek Prize program, we hope to raise public awareness of a very positive side of immigration: the way in which the intelligence, talent, and drive of immigrants helps this country to maintain its position of world leader in science and culture," says Dr. Vilcek.

"When we came to this country, we were unknown. We started here with no references or guarantees, and this country gave us the opportunity to succeed," adds Mrs. Vilcek. "It is important that this country continues to make good on its historic promise as a land of opportunity."

The Vilcek Prize will be bestowed on Dr. Massagué on Tuesday, March 21, 2006 in a gala ceremony at The Mandarin-Oriental on Columbus Circle in New York. Dr. Massagué will be introduced by Dr. Harold Varmus, co-recipient of a Nobel Prize for studies of the genetic basis of cancer and President of Memorial Sloan-Kettering Cancer Center. A second prize will also be given that night to honor achievement in the arts. The winner of the Vilcek Prize in the arts and humanities will be announced in the next few weeks.

The Vilcek Foundation

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to